Dr. Sarah Streett is the Clinical Director of Inflammatory Bowel Disease at Stanford and is passionate about taking care of people with IBD. She is a national expert in the treating of complex IBD and is expanding our services to offer multi-disciplinary care and opportunities for clinical research participation. In 2018 she received the Champion of Hope Award from the Crohn’s and Colitis Foundation and serves on their Medical Advisory Board. Her interests are in fertility and pregnancy in people with IBD, developing precision approaches to IBD therapy, and in the role that the microbiome and diet play its pathogenesis. She is one of the investigators in the Stanford IBD Registry and has research projects focused on optimizing clinical outcomes in IBD, the role of the microbiota and diet in IBD and pregnancy and applying new technologies to individualizing therapy for IBD.

Dr. Streett has a national leadership role in the American Gastroenterological Association, where has been Chair of the Practice Management and Economics Committee, as well as Chair of the AGA’s initiatives on Obesity. She currently serves on the Government Affairs Committee and is a special government employee at the FDA. She has represented the interests of gastroenterologists and their patients on Capitol Hill numerous times. Dr. Streett believes strongly in a collaborative approach to give patient’s personalized care based on the latest therapies for the treatment of IBD.

Clinical Focus

  • Gastroenterology
  • Inflammatory Bowel Disease
  • Fertility and Pregnancy in IBD
  • Transition from pediatric to adult IBD care
  • Pouchitis
  • Clinical Trials

Administrative Appointments

  • Clinical Associate Professor, Stanford University (2015 - Present)

Honors & Awards

  • Champion of Hope, Crohn's and Colitis Foundation (2018)

Professional Education

  • Board Certification: American Board of Internal Medicine, Gastroenterology (1997)
  • Fellowship: Stanford School of Medicine (1997)
  • Residency: Stanford School of Medicine (1994)
  • Internship: Stanford School of Medicine (1992)
  • Medical Education: Johns Hopkins University School of Medicine (1991) MD

Community and International Work

  • Crohn's and Colitis Medical Advisory Board


    Patient Education

    Partnering Organization(s)



    Bay Area

    Ongoing Project


    Opportunities for Student Involvement


Clinical Trials

  • Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease Recruiting

    The current multicentre phase III study is proposed to confirm in an add-on therapy design compared to a placebo-control group, the efficacy of adipose-derived stem cells (eASCs) from healthy donors for the treatment of complex anal fistulas in patients with Crohn's disease over a 24-week period and an extended follow-up period up to 104 weeks.

    View full details

Graduate and Fellowship Programs

  • Gastroenterology & Hepatology (Fellowship Program)

All Publications

  • Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. The American journal of gastroenterology Gubatan, J. n., Nielsen, O. H., Levitte, S. n., Juhl, C. B., Maxwell, C. n., Streett, S. E., Habtezion, A. n. 2020


    Biologics, such as tumor necrosis factor inhibitors, anti-integrins and anticytokines, are therapies for inflammatory bowel disease (IBD) that may increase the risk of infection. Most biologics undergo placental transfer during pregnancy and persist at detectable concentrations in exposed infants. Whether this is associated with an increased risk of infantile infections is controversial. We performed a systematic review and meta-analysis evaluating the risk of infantile infections after in utero exposure to biologics used to treat IBD.We searched PubMed, Embase, Scopus, Web of Science, and CENTRAL from inception to June 2020 to evaluate the association of biologic therapy during pregnancy in women with IBD and risk of infantile infections. Odds ratios of outcomes were pooled and analyzed using a random effects model.Nine studies met the inclusion criteria comprising 8,013 women with IBD (5,212 Crohn's disease, 2,801 ulcerative colitis) who gave birth to 8,490 infants. Biologic use during pregnancy was not associated with an increased risk of all infantile infections (odds ratio [OR] 0.91, 95% confidence interval [CI] 0.73-1.14, I = 30%). In a subgroup analysis for the type of infection, biologic use was associated with increased infantile upper respiratory infections (OR 1.57, 95% CI 1.02-2.40, I = 4%). Biologic use during pregnancy was not associated with infantile antibiotic use (OR 0.91, 95% CI 0.73-1.14, I = 30%) or infection-related hospitalizations (OR 1.33, 95% CI 0.95-1.86, I = 26%).Biologics use during pregnancy in women with IBD is not associated with the overall risk of infantile infections or serious infections requiring antibiotics or hospitalizations but is associated with an increased risk of upper respiratory infections.

    View details for DOI 10.14309/ajg.0000000000000910

    View details for PubMedID 33110017

  • A Failure to Communicate: Disentangling the Causes of Perianal Fistula in Crohn's Disease and Anal Squamous Cell Cancer. Digestive diseases and sciences Weingarden, A. R., Smith, P., Streett, S., Triadafilopoulos, G. 2020

    View details for DOI 10.1007/s10620-020-06130-8

    View details for PubMedID 32037474

  • Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Nielsen, O. H., Gubatan, J. M., Juhl, C. B., Streett, S. E., Maxwell, C. n. 2020


    Biologics are routinely used in pregnant women with inflammatory bowel disease (IBD) but large-scale data reporting adverse pregnancy outcomes among biologic users are lacking. We sought to estimate the prevalence of adverse pregnancy outcomes in women with IBD on biologic therapies.We searched major databases from inception to June 2020 for studies estimating the prevalence of adverse pregnancy outcomes in IBD when using biologics (anti-TNF, anti-integrins, and anti-cytokines). Prevalence and relative risk (RR) were pooled using a random effects model.Forty-eight studies were included in the meta-analysis comprising 6963 patients. Biologic therapy in IBD pregnancies was associated with a pooled prevalence of 8% (95% CI 6-10%, I2= 87.4%) for early pregnancy loss, 9% (95% CI 7-11%, I2=89.9%) preterm birth, 0% (95% CI 0-0%, I2=0%) still birth, 8% (95% CI 5-10%, I2=87.0%) low birth weight, and 1% (95% CI 1-2%, I2=78.3%) congenital malformations. These rates are comparable to those published in the general population. In subgroup analyses of a small number of studies, the prevalence of early pregnancy loss and preterm birth were higher in vedolizumab versus anti-TNF users. Meta-regression did not reveal an association of disease activity or concomitant thiopurine on adverse outcomes. Continued TNF inhibitor use during the third trimester was not associated with risk of preterm birth (RR 1.41, 95% CI 0.77-2.60, I2=0%), low birth weight (RR 1.32, 95% CI 0.80-2.18, I2=0%), or congenital malformations (RR 1.28, 95% 0.47-3.49, I2=0%).Adverse pregnancy outcomes among pregnant IBD women with biologic use are comparable with that of the general population. PROSPERO protocol #CRD42019135721.

    View details for DOI 10.1016/j.cgh.2020.09.021

    View details for PubMedID 32931960

  • Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases. Nature communications Rubin, S. J., Bai, L., Haileselassie, Y., Garay, G., Yun, C., Becker, L., Streett, S. E., Sinha, S. R., Habtezion, A. 2019; 10 (1): 2686


    Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis. Each disease is characterized by a diverse set of potential manifestations, which determine patients' disease phenotype. Current understanding of phenotype determinants is limited, despite increasing prevalence and healthcare costs. Diagnosis and monitoring of disease requires invasive procedures, such as endoscopy and tissue biopsy. Here we report signatures of heterogeneity between disease diagnoses and phenotypes. Using mass cytometry, we analyze leukocyte subsets, characterize their function(s), and examine gut-homing molecule expression in blood and intestinal tissue from healthy and/or IBD subjects. Some signatures persist in IBD despite remission, and many signatures are highly represented by leukocytes that express gut trafficking molecules. Moreover, distinct systemic and local immune signatures suggest patterns of cell localization in disease. Our findings highlight the importance of gut tropic leukocytes in circulation and reveal that blood-based immune signatures differentiate clinically relevant subsets of IBD.

    View details for DOI 10.1038/s41467-019-10387-7

    View details for PubMedID 31217423

  • White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education and Resources. Clinical gastroenterology and hepatology Acosta, A., Streett, S., Kroh, M. D., Cheskin, L. J., Saunders, K. H., Kurian, M., Schofield, M., Barlow, S. E., Aronne, L. 2017


    The epidemic of obesity continues at alarming rates, with a high burden to our economy and society. The American Gastroenterological Association understands the importance of embracing obesity as a chronic, relapsing disease and supports a multidisciplinary approach to the management of obesity. Because gastrointestinal disorders resulting from obesity are more frequent and often present sooner than type 2 diabetes mellitus and cardiovascular disease, gastroenterologists have an opportunity to address obesity and provide an effective therapy early. Patients who are overweight or obese already fill gastroenterology clinics with gastroesophageal reflux disease and its associated risks of Barrett's esophagus and esophageal cancer, gallstone disease, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, and colon cancer. Obesity is a major modifiable cause of diseases of the digestive tract that frequently goes unaddressed. As internists, specialists in digestive disorders, and endoscopists, gastroenterologists are in a unique position to play an important role in the multidisciplinary treatment of obesity. This American Gastroenterological Association paper was developed with content contribution from Society of American Gastrointestinal and Endoscopic Surgeons, The Obesity Society, Academy of Nutrition and Dietetics, and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, endorsed with input by American Society for Gastrointestinal Endoscopy, American Society for Metabolic and Bariatric Surgery, American Association for the Study of Liver Diseases, and Obesity Medicine Association, and describes POWER: Practice Guide on Obesity and Weight Management, Education and Resources. Its objective is to provide physicians with a comprehensive, multidisciplinary process to guide and personalize innovative obesity care for safe and effective weight management.

    View details for DOI 10.1016/j.cgh.2016.10.023

    View details for PubMedID 28242319

  • White Paper AGA: An Episode-of-Care Framework for the Management of Obesity: Moving Towards High Value, High Quality Care: A Report from the American Gastroenterological Association Institute Obesity Episode of Care and Bundle Initiative Work Group. Clinical gastroenterology and hepatology Brill, J. V., Ashmore, J. A., Brengman, M. L., Buffington, D. E., Feldshon, S. D., Friedman, K. E., Margolis, P. S., Markus, D., Narramore, L., Rastogi, A., Starpoli, A. A., Strople, K., White, J. V., Streett, S. E. 2017


    The American Gastroenterological Association acknowledges the need for gastroenterologists to participate in and provide value-based care for both cognitive and procedural conditions. Episodes of care are designed to engage specialists in the movement toward fee for value, while facilitating improved outcomes and patient experience and a reduction in unnecessary services and overall costs. The episode of care model puts the patient at the center of all activity related to their particular diagnosis, procedure, or health care event, rather than on a physician's specific services. It encourages and incents communication, collaboration, and coordination across the full continuum of care and creates accountability for the patient's entire experience and outcome. This paper outlines a collaborative approach involving multiple stakeholders for gastrointestinal practices to assess their ability to participate in and implement an episode of care for obesity and understand the essentials of coding and billing for these services.

    View details for DOI 10.1016/j.cgh.2017.02.002

    View details for PubMedID 28238952

  • American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. Obesity (Silver Spring, Md.) Ligibel, J. A., Alfano, C. M., Hershman, D. L., Merrill, J. K., Basen-Engquist, K. n., Bloomgarden, Z. T., Demark-Wahnefried, W. n., Dixon, S. n., Hassink, S. G., Jakicic, J. M., Morton, J. M., Okwuosa, T. M., Powell-Wiley, T. M., Rothberg, A. E., Stephens, M. n., Streett, S. E., Wild, R. A., Westman, E. A., Williams, R. J., Wollins, D. S., Hudis, C. A. 2017; 25 Suppl 2: S34–S39


    Given the increasing evidence that obesity increases the risk of developing and dying from malignancy, the American Society of Clinical Oncology (ASCO) launched an Obesity Initiative in 2013 that was designed to increase awareness among oncology providers and the general public of the relationship between obesity and cancer and to promote research in this area. Recognizing that the type of societal change required to impact the obesity epidemic will require a broad-based effort, ASCO hosted the "Summit on Addressing Obesity through Multidisciplinary Collaboration" in 2016.This meeting was held to review current challenges in addressing obesity within the respective health care provider communities and to identify priorities that would most benefit from a collective and cross-disciplinary approach.Efforts focused on four key areas: provider education and training; public education and activation; research; and policy and advocacy. Summit attendees discussed current challenges in addressing obesity within their provider communities and identified priorities that would most benefit from multidisciplinary collaboration.A synopsis of recommendations to facilitate future collaboration, as well as examples of ongoing cooperative efforts, provides a blueprint for multidisciplinary provider collaboration focused on obesity prevention and treatment.

    View details for PubMedID 29086516

  • Our Practices, Ourselves: How do we establish a Personal Connection with our Patients AGA Perspectives Streett, S. E. 2010; 6 (4): 16
  • Endoscopic colorectal cancer screening in women: can we do better? GASTROINTESTINAL ENDOSCOPY Streett, S. E. 2007; 65 (7): 1047-1049

    View details for DOI 10.1016/j.gie.2007.02.037

    View details for Web of Science ID 000247216300018

    View details for PubMedID 17531639

  • Does gender affect career satisfaction and advancement in gastroenterology? Results of an AGA institute-sponsored survey Digestive Disease Week/107th Annual Meeting of the American-Gastroenterological-Association Gerson, L. B., Twomey, K., Hecht, G., Lee, L., McQuaid, K., Pizarro, T. T., Street, S., Yoshida, C., Early, D. W B SAUNDERS CO-ELSEVIER INC. 2007: 1598–1606


    Women comprise 19% of the American Gastroenterological Association (AGA) membership. We performed a prospective study to determine whether female gastroenterologists were less likely to achieve career advancement and satisfaction.We administered an online survey to AGA members from 2004-2006. The survey contained questions regarding effects of gender on career advancement, satisfaction with career, promotional policies, and integration of family and career.A total of 457 individuals (response rate 9% after 2 major invitations) completed the survey, including 262 (57%) women (20% in private practice, 53% in academic careers, and 27% trainees) and 195 men (23% in private practice, 58% in academic careers, and 19% trainees). The male gastroenterologists were significantly older (P < .005) and in their careers for significantly more years (P = .002). There were no significant differences with respect to marital status, number of children, or number of hours worked between the genders. Men were more likely to achieve the rank of full professor (P = .035), and significantly more women reported that gender affected their career advancement (47% vs 9%; P < .001). Women in academic careers reported less satisfaction with their careers (P = .01) and perceived more difficulty in achieving promotion and tenure. Women were more likely to choose private practice careers because of part-time options (P = .025). Equal numbers of men and women in practice reported difficulty balancing work and family life.Significantly more female than male gastroenterologists perceive that gender has affected their career advancement. Female academic gastroenterologists reported less overall career satisfaction and promotion than male academic gastroenterologists.

    View details for DOI 10.1053/j.gastro.2007.02.045

    View details for Web of Science ID 000246020900043

    View details for PubMedID 17408634